Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders

• Source: Shutterstock

Related Content

Bausch CEO Papa Will Head Eye Health Biz Under Strategic Review

May 06 2021

Pfizer/Allergan: An American Icon Heads For Greener (Tax) Pastures

Nov 23 2015

Teva Gets What It Wants – Allergan Generics, Not Mylan

Aug 03 2015

Forest Cuts A New Path But Remains Rooted In Primary Care

Dec 03 2013

Bausch + Lomb CEO Leaving 10 Weeks Following IPO, Month After Icahn Gains Two Board Seats

Jul 22 2022

Big paydays ahead as Actavis buys Allergan for $219/share

Nov 18 2014

Valeant: Another Fine Mess

Mar 02 2016

Forest's Saunders ropes 2nd major sale, boosts personal brand in Actavis deal

Feb 19 2014

AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan

Jun 25 2019

Finance Watch: Brent Saunders Plots Return To Deal-Making With A SPAC IPO

Sep 11 2020

Bausch Investors Initially Pessimistic Following B+L Spinout

May 10 2022

Related Companies

Bausch Health Companies Inc.

Valeant

Forest Laboratories, Inc.

Actavis Group

Allergan plc

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Additional Topics

Executive Changes Business Strategies Consumer Companies M & A Leadership Dietary Supplements Manufacturing OTC Drugs BioPharmaceutical Ophthalmic

More from Leadership

More from HBW Insight

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window